Date of report 13 May 2019
Reported case interaction between
 Rilpivirine and OMEPRAZOL

FLS Science

Drugs suspected to be involved in the DDI

Victim
Rilpivirine
Daily Dose
25 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Dec. 19, 2016
End date
Ongoing
Perpetrator
OMEPRAZOL
Daily Dose
20 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Unknown
End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment
Dolutegravir
Lamivudine
Rilpivirine
Complete list of all comedications taken by the patient, included that involved in the DDI

Omeprazol, desloratadine, ipratropium bromide, escitalopram, furosemide, folic acid, lorazepam, magnesium, calcium, paracetamol, quetiapine, salbutamol, trimetroprim, sulphametoxazol, terbutaline, trazodone.

Clinical case description

Gender
Female
Age
54
eGFR (mL/min)
Hemodialysis
Liver function impairment
No
Description

Despite potential interacion between rilpivirine and omeprazol, viral load continued being undetectable. Treatment with rilpivirine plus omeprazol (20 mg qd) was maintained.

Clinical Outcome

No unwanted outcome

Editorial Comment

Rilpivirine should not be co-administered with omeprazole as significant decreases in rilpivirine plasma concentrations may occur (due to gastric pH increase), which may result in loss of therapeutic effect of rilpivirine.

University of Liverpool Recommendation

These drugs should not be coadministered
For more information click here